Zhang Y, Wu Q L, Yun J P
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Pathological Department, Sun Yat-sen University, Cancer Center, Guangzhou 510060, China.
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018 Sep 7;53(9):718-720. doi: 10.3760/cma.j.issn.1673-0860.2018.09.020.
In recent years, the incidence of thyroid carcinoma gradually increased in China. The pathology diagnosis and classification was based on WHO classification of Tumors of Endocrine Organs, the third edition which published in 2004. The fourth edition, WHO classification of Tumors of Endocrine Organs was published in July 2017. Compared with the third, some important aspects (or points) were revised: the ICD-O code of hyalinizing trabecular tumor was changed from 0 to 1; three other encapsulated follicular-patterned thyroid tumors were added; the variants of well differentiation thyroid carcinoma (including papillary carcinoma and follicular carcinoma ) which was originated from thyroid epithelial cells were updated; oncocytic cell tumors were separated from follicular tumors; the ICD-O code of ectopic thymoma was changed from 1 to 3. Refinement and standardization part of the concepts and diagnostic criterias were done which can solve practical problems in pathology diagnosis.
近年来,中国甲状腺癌的发病率逐渐上升。病理诊断和分类依据的是2004年出版的《WHO内分泌器官肿瘤分类》第三版。《WHO内分泌器官肿瘤分类》第四版于2017年7月出版。与第三版相比,一些重要方面(或要点)有所修订:透明变梁状肿瘤的ICD-O编码从0变为1;新增了另外三种包膜滤泡型甲状腺肿瘤;源自甲状腺上皮细胞的高分化甲状腺癌(包括乳头状癌和滤泡状癌)的变异型得到更新;嗜酸性细胞瘤从滤泡性肿瘤中分离出来;异位胸腺瘤的ICD-O编码从1变为3。对部分概念和诊断标准进行了细化和规范,可解决病理诊断中的实际问题。